Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice

Even Fjære, Ulrike L. Aune, Kristin Røen, Alison H. Keenan, Tao Ma, Kamil Borkowski, David M. Kristensen, Guy W. Novotny, Thomas Mandrup-Poulsen, Brian D. Hudson, Graeme Milligan, Yannan Xi, John W. Newman, Fawaz Haj, Bjørn Liaset, Karsten Kristiansen, Lise Madsena

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Chronic low grade inflammation is closely linked to obesityassociated insulin resistance. To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (γINDO) for 7 weeks. Development of obesity, insulin resistance, and glucose intolerance was monitored, and the effect of indomethacin on glucose-stimulated insulin secretion (GSIS) was measured in vivo and in vitro using MIN6β-cells. We found that supplementation with indomethacin prevented HF/HS-induced obesity and diet-induced changes in systemic insulin sensitivity. Thus, HF/HSαINDOfed mice remained insulin-sensitive. However, mice fed HF/HSαINDO exhibited pronounced glucose intolerance. Hepatic glucose output was significantly increased. Indomethacin had no effect on adipose tissue mass, glucose tolerance, or GSIS when included in a regular diet. Indomethacin administration to obese mice did not reduce adipose tissue mass, and the compensatory increase in GSIS observed in obese mice was not affected by treatment with indomethacin. We demonstrate that indomethacin did not inhibit GSIS per se, but activation of GPR40 in the presence of indomethacin inhibited glucose-dependent insulin secretion in MIN6 cells. We conclude that constitutive high hepatic glucose output combined with impaired GSIS in response to activation of GPR40-dependent signaling in the HF/HS+ INDO-fed mice contributed to the impaired glucose clearance during a glucose challenge and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF/HS diet.

Original languageEnglish (US)
Pages (from-to)16032-16045
Number of pages14
JournalJournal of Biological Chemistry
Volume289
Issue number23
DOIs
StatePublished - Jun 6 2014

Fingerprint

Glucose Intolerance
High Fat Diet
Nutrition
Inbred C57BL Mouse
Indomethacin
Insulin Resistance
Obesity
Fats
Insulin
Glucose
Sucrose
Obese Mice
Diet
Adipose Tissue
Chemical activation
Tissue
Cyclooxygenase Inhibitors
Liver
Anti-Inflammatory Agents
Inflammation

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice. / Fjære, Even; Aune, Ulrike L.; Røen, Kristin; Keenan, Alison H.; Ma, Tao; Borkowski, Kamil; Kristensen, David M.; Novotny, Guy W.; Mandrup-Poulsen, Thomas; Hudson, Brian D.; Milligan, Graeme; Xi, Yannan; Newman, John W.; Haj, Fawaz; Liaset, Bjørn; Kristiansen, Karsten; Madsena, Lise.

In: Journal of Biological Chemistry, Vol. 289, No. 23, 06.06.2014, p. 16032-16045.

Research output: Contribution to journalArticle

Fjære, E, Aune, UL, Røen, K, Keenan, AH, Ma, T, Borkowski, K, Kristensen, DM, Novotny, GW, Mandrup-Poulsen, T, Hudson, BD, Milligan, G, Xi, Y, Newman, JW, Haj, F, Liaset, B, Kristiansen, K & Madsena, L 2014, 'Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice', Journal of Biological Chemistry, vol. 289, no. 23, pp. 16032-16045. https://doi.org/10.1074/jbc.M113.525220
Fjære, Even ; Aune, Ulrike L. ; Røen, Kristin ; Keenan, Alison H. ; Ma, Tao ; Borkowski, Kamil ; Kristensen, David M. ; Novotny, Guy W. ; Mandrup-Poulsen, Thomas ; Hudson, Brian D. ; Milligan, Graeme ; Xi, Yannan ; Newman, John W. ; Haj, Fawaz ; Liaset, Bjørn ; Kristiansen, Karsten ; Madsena, Lise. / Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice. In: Journal of Biological Chemistry. 2014 ; Vol. 289, No. 23. pp. 16032-16045.
@article{92f65d9091414256b61dbdb2900f1e4b,
title = "Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice",
abstract = "Chronic low grade inflammation is closely linked to obesityassociated insulin resistance. To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (γINDO) for 7 weeks. Development of obesity, insulin resistance, and glucose intolerance was monitored, and the effect of indomethacin on glucose-stimulated insulin secretion (GSIS) was measured in vivo and in vitro using MIN6β-cells. We found that supplementation with indomethacin prevented HF/HS-induced obesity and diet-induced changes in systemic insulin sensitivity. Thus, HF/HSαINDOfed mice remained insulin-sensitive. However, mice fed HF/HSαINDO exhibited pronounced glucose intolerance. Hepatic glucose output was significantly increased. Indomethacin had no effect on adipose tissue mass, glucose tolerance, or GSIS when included in a regular diet. Indomethacin administration to obese mice did not reduce adipose tissue mass, and the compensatory increase in GSIS observed in obese mice was not affected by treatment with indomethacin. We demonstrate that indomethacin did not inhibit GSIS per se, but activation of GPR40 in the presence of indomethacin inhibited glucose-dependent insulin secretion in MIN6 cells. We conclude that constitutive high hepatic glucose output combined with impaired GSIS in response to activation of GPR40-dependent signaling in the HF/HS+ INDO-fed mice contributed to the impaired glucose clearance during a glucose challenge and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF/HS diet.",
author = "Even Fj{\ae}re and Aune, {Ulrike L.} and Kristin R{\o}en and Keenan, {Alison H.} and Tao Ma and Kamil Borkowski and Kristensen, {David M.} and Novotny, {Guy W.} and Thomas Mandrup-Poulsen and Hudson, {Brian D.} and Graeme Milligan and Yannan Xi and Newman, {John W.} and Fawaz Haj and Bj{\o}rn Liaset and Karsten Kristiansen and Lise Madsena",
year = "2014",
month = "6",
day = "6",
doi = "10.1074/jbc.M113.525220",
language = "English (US)",
volume = "289",
pages = "16032--16045",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "23",

}

TY - JOUR

T1 - Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice

AU - Fjære, Even

AU - Aune, Ulrike L.

AU - Røen, Kristin

AU - Keenan, Alison H.

AU - Ma, Tao

AU - Borkowski, Kamil

AU - Kristensen, David M.

AU - Novotny, Guy W.

AU - Mandrup-Poulsen, Thomas

AU - Hudson, Brian D.

AU - Milligan, Graeme

AU - Xi, Yannan

AU - Newman, John W.

AU - Haj, Fawaz

AU - Liaset, Bjørn

AU - Kristiansen, Karsten

AU - Madsena, Lise

PY - 2014/6/6

Y1 - 2014/6/6

N2 - Chronic low grade inflammation is closely linked to obesityassociated insulin resistance. To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (γINDO) for 7 weeks. Development of obesity, insulin resistance, and glucose intolerance was monitored, and the effect of indomethacin on glucose-stimulated insulin secretion (GSIS) was measured in vivo and in vitro using MIN6β-cells. We found that supplementation with indomethacin prevented HF/HS-induced obesity and diet-induced changes in systemic insulin sensitivity. Thus, HF/HSαINDOfed mice remained insulin-sensitive. However, mice fed HF/HSαINDO exhibited pronounced glucose intolerance. Hepatic glucose output was significantly increased. Indomethacin had no effect on adipose tissue mass, glucose tolerance, or GSIS when included in a regular diet. Indomethacin administration to obese mice did not reduce adipose tissue mass, and the compensatory increase in GSIS observed in obese mice was not affected by treatment with indomethacin. We demonstrate that indomethacin did not inhibit GSIS per se, but activation of GPR40 in the presence of indomethacin inhibited glucose-dependent insulin secretion in MIN6 cells. We conclude that constitutive high hepatic glucose output combined with impaired GSIS in response to activation of GPR40-dependent signaling in the HF/HS+ INDO-fed mice contributed to the impaired glucose clearance during a glucose challenge and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF/HS diet.

AB - Chronic low grade inflammation is closely linked to obesityassociated insulin resistance. To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (γINDO) for 7 weeks. Development of obesity, insulin resistance, and glucose intolerance was monitored, and the effect of indomethacin on glucose-stimulated insulin secretion (GSIS) was measured in vivo and in vitro using MIN6β-cells. We found that supplementation with indomethacin prevented HF/HS-induced obesity and diet-induced changes in systemic insulin sensitivity. Thus, HF/HSαINDOfed mice remained insulin-sensitive. However, mice fed HF/HSαINDO exhibited pronounced glucose intolerance. Hepatic glucose output was significantly increased. Indomethacin had no effect on adipose tissue mass, glucose tolerance, or GSIS when included in a regular diet. Indomethacin administration to obese mice did not reduce adipose tissue mass, and the compensatory increase in GSIS observed in obese mice was not affected by treatment with indomethacin. We demonstrate that indomethacin did not inhibit GSIS per se, but activation of GPR40 in the presence of indomethacin inhibited glucose-dependent insulin secretion in MIN6 cells. We conclude that constitutive high hepatic glucose output combined with impaired GSIS in response to activation of GPR40-dependent signaling in the HF/HS+ INDO-fed mice contributed to the impaired glucose clearance during a glucose challenge and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF/HS diet.

UR - http://www.scopus.com/inward/record.url?scp=84902211945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902211945&partnerID=8YFLogxK

U2 - 10.1074/jbc.M113.525220

DO - 10.1074/jbc.M113.525220

M3 - Article

C2 - 24742673

AN - SCOPUS:84902211945

VL - 289

SP - 16032

EP - 16045

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 23

ER -